Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker LTGO
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G | LTGO Latigo Biotherapeutics, Inc. | Blue Owl Capital Holdings LP | 3.60M | 5.4% | SCHEDULE 13G ↗ |
| Nov 6, 2026 | SCHEDULE 13G/A (amended) | LTGO Latigo Biotherapeutics, Inc. | Len Blavatnik | 3.19M | 4.8% | SCHEDULE 13G/A ↗ |
| Nov 6, 2026 | SCHEDULE 13G/A (amended) | LTGO Latigo Biotherapeutics, Inc. | Access Industries Management, LLC | 3.19M | 4.8% | SCHEDULE 13G/A ↗ |
| Nov 6, 2026 | SCHEDULE 13G/A (amended) | LTGO Latigo Biotherapeutics, Inc. | Access Industries Holdings LLC | 3.19M | 4.8% | SCHEDULE 13G/A ↗ |
| Nov 6, 2026 | SCHEDULE 13G/A (amended) | LTGO Latigo Biotherapeutics, Inc. | AI Biotechnology LLC | 3.19M | 4.8% | SCHEDULE 13G/A ↗ |
| Oct 29, 2026 | SCHEDULE 13G | LTGO Latigo Biotherapeutics, Inc. | Dr. Beth C. Seidenberg | 13.20M | 19.9% | SCHEDULE 13G ↗ |
| Oct 29, 2026 | SCHEDULE 13G | LTGO Latigo Biotherapeutics, Inc. | Westlake BioPartners Opportunity GP I, LLC | 2.09M | 3.2% | SCHEDULE 13G ↗ |
| Oct 29, 2026 | SCHEDULE 13G | LTGO Latigo Biotherapeutics, Inc. | Westlake BioPartners Opportunity Fund I, L.P. | 2.09M | 3.2% | SCHEDULE 13G ↗ |
| Oct 29, 2026 | SCHEDULE 13G | LTGO Latigo Biotherapeutics, Inc. | Westlake BioPartners GP II, LLC | 5.16M | 7.8% | SCHEDULE 13G ↗ |
| Oct 29, 2026 | SCHEDULE 13G | LTGO Latigo Biotherapeutics, Inc. | Westlake BioPartners Fund II, L.P. | 5.16M | 7.8% | SCHEDULE 13G ↗ |
| Oct 29, 2026 | SCHEDULE 13G | LTGO Latigo Biotherapeutics, Inc. | Westlake BioPartners GP I, LLC | 5.94M | 9.0% | SCHEDULE 13G ↗ |
| Oct 29, 2026 | SCHEDULE 13G | LTGO Latigo Biotherapeutics, Inc. | Westlake BioPartners Fund I, L.P. | 5.94M | 9.0% | SCHEDULE 13G ↗ |
| Aug 18, 2026 | SCHEDULE 13G | LTGO Latigo Biotherapeutics, Inc. | Len Blavatnik | 3.19M | 5.0% | SCHEDULE 13G ↗ |
| Aug 18, 2026 | SCHEDULE 13G | LTGO Latigo Biotherapeutics, Inc. | Access Industries Management, LLC | 3.19M | 5.0% | SCHEDULE 13G ↗ |
| Aug 18, 2026 | SCHEDULE 13G | LTGO Latigo Biotherapeutics, Inc. | Access Industries Holdings LLC | 3.19M | 5.0% | SCHEDULE 13G ↗ |
| Aug 18, 2026 | SCHEDULE 13G | LTGO Latigo Biotherapeutics, Inc. | AI Biotechnology LLC | 3.19M | 5.0% | SCHEDULE 13G ↗ |
| Aug 17, 2026 | SCHEDULE 13G | LTGO Latigo Biotherapeutics, Inc. | RA Capital Healthcare Fund, L.P. | 5.30M | 8.4% | SCHEDULE 13G ↗ |
| Aug 17, 2026 | SCHEDULE 13G | LTGO Latigo Biotherapeutics, Inc. | Rajeev Shah | 5.30M | 8.4% | SCHEDULE 13G ↗ |
| Aug 17, 2026 | SCHEDULE 13G | LTGO Latigo Biotherapeutics, Inc. | Peter Kolchinsky | 5.30M | 8.4% | SCHEDULE 13G ↗ |
| Aug 17, 2026 | SCHEDULE 13G | LTGO Latigo Biotherapeutics, Inc. | RA Capital Management, L.P. | 5.30M | 8.4% | SCHEDULE 13G ↗ |
| Aug 17, 2026 | SCHEDULE 13D | LTGO Latigo Biotherapeutics, Inc. | James B. Tananbaum | 9.18M | 14.5% | SCHEDULE 13D ↗ |
| Aug 17, 2026 | SCHEDULE 13D | LTGO Latigo Biotherapeutics, Inc. | Foresite Capital Opportunity Management V, LLC | 3.41M | 5.4% | SCHEDULE 13D ↗ |
| Aug 17, 2026 | SCHEDULE 13D | LTGO Latigo Biotherapeutics, Inc. | Foresite Capital Opportunity Fund V, L.P. | 3.41M | 5.4% | SCHEDULE 13D ↗ |
| Aug 17, 2026 | SCHEDULE 13D | LTGO Latigo Biotherapeutics, Inc. | Foresite Capital Management V, LLC | 3.56M | 5.6% | SCHEDULE 13D ↗ |
| Aug 17, 2026 | SCHEDULE 13D | LTGO Latigo Biotherapeutics, Inc. | Foresite Capital Fund V, L.P. | 3.56M | 5.6% | SCHEDULE 13D ↗ |
| Aug 17, 2026 | SCHEDULE 13D | LTGO Latigo Biotherapeutics, Inc. | Foresite Capital Management VI, LLC | 2.20M | 3.5% | SCHEDULE 13D ↗ |
| Aug 17, 2026 | SCHEDULE 13D | LTGO Latigo Biotherapeutics, Inc. | Foresite Capital Fund VI LP | 2.20M | 3.5% | SCHEDULE 13D ↗ |
| Aug 13, 2026 | SCHEDULE 13G | LTGO Latigo Biotherapeutics, Inc. | David Kroin | 4.45M | 7.0% | SCHEDULE 13G ↗ |
| Aug 13, 2026 | SCHEDULE 13G | LTGO Latigo Biotherapeutics, Inc. | Deep Track Biotechnology Master Fund, Ltd. | 4.45M | 7.0% | SCHEDULE 13G ↗ |
| Aug 13, 2026 | SCHEDULE 13G | LTGO Latigo Biotherapeutics, Inc. | Deep Track Capital, LP | 4.45M | 7.0% | SCHEDULE 13G ↗ |
30 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 7:36 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances